Overview

A Phase I Study of XJ103 in Chinese Healthy Subjects

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-03-06
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria. Subjects will be assigned to one of four different dosage cohorts. Subjects in each cohort will randomly be given experimental drug or a placebo.
Phase:
PHASE1
Details
Lead Sponsor:
Starmab biologics(Shanghai)Co,.ltd